Cargando…

Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia

Sodium zirconium cyclosilicate (Lokelma™) [hereafter referred to as SZC] is a non-absorbed, non-polymer zirconium silicate compound that preferentially exchanges hydrogen and sodium for potassium and ammonium ions in the gastrointestinal tract (GIT), thereby increasing faecal potassium excretion and...

Descripción completa

Detalles Bibliográficos
Autor principal: Hoy, Sheridan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433811/
https://www.ncbi.nlm.nih.gov/pubmed/30306338
http://dx.doi.org/10.1007/s40265-018-0991-6
_version_ 1783406346439229440
author Hoy, Sheridan M.
author_facet Hoy, Sheridan M.
author_sort Hoy, Sheridan M.
collection PubMed
description Sodium zirconium cyclosilicate (Lokelma™) [hereafter referred to as SZC] is a non-absorbed, non-polymer zirconium silicate compound that preferentially exchanges hydrogen and sodium for potassium and ammonium ions in the gastrointestinal tract (GIT), thereby increasing faecal potassium excretion and lowering serum potassium levels. It is available as a powder for oral suspension (in water) and is approved in the EU and the USA for the treatment of hyperkalaemia in adults. In two multinational, phase III studies in adults with hyperkalaemia, SZC 10 g three times daily lowered serum potassium levels to within the normal range (3.5–5.0 mmol/L) during the first 48 h of treatment, and SZC 5 and 10 g once daily maintained normokalaemia over ≤ 28 days’ therapy. These beneficial effects were consistent across all patient subgroups (e.g. chronic kidney disease, diabetes, heart failure, concomitant use of RAAS inhibitor therapy), and appeared to be maintained over the longer term (≤ 12 months). SZC was generally well tolerated in adults with hyperkalaemia. Its tolerability profile was generally similar to that seen with placebo over ≤ 28 day, and its safety profile appeared to remain consistent over the longer term (≤ 12 months). Moreover, the incidence of hypokalemia was low. Current evidence indicates that SZC is a promising therapy for the management of hyperkalaemia in adults.
format Online
Article
Text
id pubmed-6433811
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-64338112019-04-12 Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia Hoy, Sheridan M. Drugs Adis Drug Evaluation Sodium zirconium cyclosilicate (Lokelma™) [hereafter referred to as SZC] is a non-absorbed, non-polymer zirconium silicate compound that preferentially exchanges hydrogen and sodium for potassium and ammonium ions in the gastrointestinal tract (GIT), thereby increasing faecal potassium excretion and lowering serum potassium levels. It is available as a powder for oral suspension (in water) and is approved in the EU and the USA for the treatment of hyperkalaemia in adults. In two multinational, phase III studies in adults with hyperkalaemia, SZC 10 g three times daily lowered serum potassium levels to within the normal range (3.5–5.0 mmol/L) during the first 48 h of treatment, and SZC 5 and 10 g once daily maintained normokalaemia over ≤ 28 days’ therapy. These beneficial effects were consistent across all patient subgroups (e.g. chronic kidney disease, diabetes, heart failure, concomitant use of RAAS inhibitor therapy), and appeared to be maintained over the longer term (≤ 12 months). SZC was generally well tolerated in adults with hyperkalaemia. Its tolerability profile was generally similar to that seen with placebo over ≤ 28 day, and its safety profile appeared to remain consistent over the longer term (≤ 12 months). Moreover, the incidence of hypokalemia was low. Current evidence indicates that SZC is a promising therapy for the management of hyperkalaemia in adults. Springer International Publishing 2018-10-10 2018 /pmc/articles/PMC6433811/ /pubmed/30306338 http://dx.doi.org/10.1007/s40265-018-0991-6 Text en © Springer Nature 2019, corrected publication 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
spellingShingle Adis Drug Evaluation
Hoy, Sheridan M.
Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
title Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
title_full Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
title_fullStr Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
title_full_unstemmed Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
title_short Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
title_sort sodium zirconium cyclosilicate: a review in hyperkalaemia
topic Adis Drug Evaluation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433811/
https://www.ncbi.nlm.nih.gov/pubmed/30306338
http://dx.doi.org/10.1007/s40265-018-0991-6
work_keys_str_mv AT hoysheridanm sodiumzirconiumcyclosilicateareviewinhyperkalaemia